Cassava Sciences Inc (SAVA) Stock: Evaluating the Market Performance
Moreover, the 36-month beta value for SAVA is -0.44. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0
Moreover, the 36-month beta value for SAVA is -0.44. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0
The stock of Cassava Sciences Inc (NASDAQ: SAVA) has increased by 12.85 when compared to last closing price of 18.44. Despite this, the company has
In the past week, SAVA stock has gone down by -13.48%, with a monthly decline of -13.40% and a quarterly plunge of -10.39%. The volatility
The 36-month beta value for SAVA is also noteworthy at -0.39. The public float for SAVA is 38.25M, and at present, short sellers hold a
Moreover, the 36-month beta value for SAVA is -0.39. The public float for SAVA is 38.26M and currently, short sellers hold a 34.85% of that
Cassava Sciences Inc. (SAVA) grew significantly in the past year. A Phase II study of a new Alzheimer’s treatment received a positive response from investors.
© 2024, Fueled by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.